Table 3.
Effect of TVL on liver antioxidant enzymes, TBARS and plasma nitric oxide levels in rats
| Parameters | Experimental groups | ||||
|---|---|---|---|---|---|
| NDC | DC | D + TVL 60 | D + TVL 120 | D + glibenclamide | |
| Liver parameters: | |||||
| SOD (% Inhibition) | 89.88 ± 2.71 | 43.82 ± 4.81** | 72.71 ± 5.89# | 74.08 ± 3.26# | 80.56 ± 7.35## |
| GPx (mU/ml) | 6.62 ± 0.23 | 1.46 ± 0.57** | 4.03 ± 0.75# | 6.44 ± 0.47## | 6.28 ± 0.86## |
| Catalase (mU/ml) | 0.34 ± 0.08 | 0.13 ± 0.02* | 0.44 ± 0.05# | 0.42 ± 0.08# | 0.61 ± 0.07# |
| TBARS (nmol/mg tissue) | 4.80 ± 1.65 | 9.86 ± 0.0.59* | 7.18 ± 0.39# | 5.53 ± 1.27# | 7.84 ± 0.97 |
| Plasma NO (uM) | 32.61 ± 1.18 | 24.35 ± 0.97** | 30.44 ± 1.64# | 34.85 ± 3.31# | 30.74 ± 3.66# |
Non-diabetic control (NDC) and diabetic control (DC); TVL 60 mg/kg.b.w. TVL 120 mg/kg.b.w. (D + TVL 120) and glibenclamide 10 mg/kg.b.w. (D + glibenclamide). All data are expressed as mean ± SEM for 7 animals per group
*Significantly different from non-diabetic control p < 0.05
**Significantly different from non-diabetic control p < 0.01
#Significantly different from diabetic control p < 0.05
##Significantly different from diabetic control p < 0.01